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Objective: Bladder dysfunctions are common inmultiple sclerosis (MS) often causing themost distressing symp-
toms. The aim of this paper was to evaluate the effectiveness of sacral nerve modulation (SNM) in this disease.
Methods:We conducted an observational retrospective survey in 17 patients treatedwith SNM in the north-east
of Italy, all complaining of bladder symptoms (storage in 41%, voiding in 24%,mixed in 35%) unresponsive to con-
ventional therapies, with a mean follow-up of 52± 26 months andmean Expanded Disability Status Scale score
of 5.8 ± 1.8.
Results: 75% of patients reported signiﬁcant and lasting improvement in bladder symptoms and in quality of life.
We observed a statistically signiﬁcant improvement in frequency, urgency, number of pads, residual volumes,
number of catheterizations and in the voided volumes.
In 5 out of 6 cases with mixed symptoms the stimulation was discontinued (device totally explanted or turned
off) after a mean time of 66 months (range 10–84 months) after the implant, for disease progression or loss of
efﬁcacy.
Conclusion: SNM could be an option in very selected cases of storage and voiding symptoms refractory to conser-
vative treatments caused by a stable or slowly progressive MS considering its minimal invasiveness and revers-
ibility. The poor results observed suggest avoiding this therapy in mixed symptoms and in cases of advanced
disability.© 2014 Elsevier B.V. All rights reserved.1. Introduction
Multiple sclerosis (MS) is a chronic inﬂammatory, demyelinating,
neurodegenerative disorder affecting the central nervous system
(CNS)with unknown etiology [1] and it represents the commonest pro-
gressive neurological disease affecting young people.
Bladder dysfunctions are common in people with MS, occurring in
up to 75% of patients during the course of the disease; they can cause
some of the most distressing symptoms, with a great impact on the
quality of life (QoL), and are often associated with signiﬁcant morbidity
[2]. Urinary symptomatology is polymorphic and, like its incidence, sub-
ject to change over time, but it tends to increase with disease progres-
sion and it is mainly the result of spinal cord involvement. The most
frequent are storage symptoms (urinary frequency, urgency, and urge
incontinence) while voiding symptoms (hesitancy, incomplete voiding
and urinary retention) exist to a lesser degree [3]. Therapeutic optionseneral Hospital of Mirano, Via
12797; fax: +39 041 5794599.for storage symptoms vary and they include, with or without associated
clean intermittent self-catheterization, conservative treatments such as
anticholinergic drugs— although the published data provide limited ev-
idence for their efﬁcacy in MS [4,5]. In patients with severe bladder
overactivity unresponsive to anticholinergics there is evidence for the
use of bladder injections of botulinum toxin A [6,7] and also emerging
evidence on the use of cannabinoids [8] and tibial nerve stimulation
[9]. Surgical procedures, which have been advocated with varying
success [10], are a last resort being irreversible, with a risk of major op-
erative morbidity and long-term consequences; they include augmen-
tation cystoplasty [11], in which the bladder is transected and
repairedwith a patch of ileum isolated from the small intestine, and uri-
nary diversion [12].
Sacral nerve modulation (SNM) is a safe and minimally invasive
treatment and it has become an option in refractory low urinary tract
symptoms (LUTS) from different underlying diseases [13–16]; a num-
ber of prospective trials and numerous case series have provided an ev-
idence base that has conﬁrmed the efﬁcacy and durability of SNM [17].
Despite the documented clinical beneﬁt, the exact underlying neuro-
physiological mechanism of action of SNM is complex and not fully
Table 1
EDSS score in different LUTS, at baseline and during SNM.
N Baseline EDSS Follow-up EDSS
All patients, mean (SD) 17 5.8 (1.8) 6.3 (2.1)
Voiding symptom, mean (SD) 4 6.5 (1.8) 6.5 (1.9)
Storage symptoms, mean (SD) 7 5.1 (2.1) 5.4 (2.2)
Mixed symptoms, mean (SD) 6 6.8 (0.5) 7.9 (0.9)
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exerts its effect through afferent pathways that modulate the activity in
other neural pathways within the spinal cord and higher centers [18].
Some studies have just investigated the effects of SNM on the higher
centers. Braun et al. [19] performed serial electroencephalograms
(EEG) in 10 patients with both neurogenic and idiopathic bladder dys-
function who had permanent implants of SNM in S3, using an on–off
paradigm with 1.5 s with stimulation “on” followed by a 10 second
stimulation “off”. They demonstrated in all patients a cortical potential
complex following stimulation with an early electronegative compo-
nent at 50 ms followed by a late potential component with a mean
latency of 253 ms, both with a maximum in the post-central gyrus.
These ﬁndings occurred irrespective of patients' reports of actually
feeling the SNM being switched on and off, whereby the authors
concluded that, although these potentials are similar to cognitively
mediated “event-related potentials”, they are clearly distinct from any
subjective sensory or even painful response and support the potential
role of suprasacral centers in SMN, most probably in the sensory cortex
areas [19].
Blok et al. [20] used positron emission tomography (PET) to study
the brain effects of SNM in patients with urge incontinence comparing
chronic (in whom SNMwas switched on for N6 months) and acute pa-
tients (neurostimulator activated for the ﬁrst time in PET scanner). They
observed different modiﬁcations in cerebral blood ﬂow in different
areas during the chronic and acute stimulations. On the basis of these
ﬁndings, the authors suggested that chronic SNM inﬂuences, presum-
ably via the spinal cord, brain areas previously implicated in bladder
overactivity, awareness of bladder ﬁlling, the urge to void and the
timing of micturition and, furthermore, areas involved in alertness and
awareness. On the other hand acute SNM modulates predominantly
areas involved in sensorimotor learning, which might become less ac-
tive during the course of chronic SNM [20].
Since few data are available about this treatment for LUTS in MS
[21–23], in the present retrospective evaluation we wanted to deter-
mine whether SNM beneﬁts patients with LUTS caused by this disease
and unresponsive to ﬁrst line conservative treatment and to assess if
there is any difference in the responsiveness degree of different
symptoms.
2. Materials and methods
In July 2008, we proposed to the Departments of Urology in the
north-east of Italy performing SNM a retrospective survey about the ef-
fectiveness of SNM inMS patients. Only in 3 departmentswas SMS used
in MS patients and all the MS patients implanted in these centers were
included in the survey. A questionnaire has been ﬁlled for each included
subject, enquiring about general data,MS features, perceived changes in
micturition symptomsafter SNMand changes coming frommicturition-
diaries. The post-voiding residual volumewas evaluated by the clean in-
termittent catheterization which is usually performed by patients with
voiding and mixed symptoms.
A visual analogic scale (VAS) was used to assess the improvement of
the QoL and the symptom urinary urgency. Outcome data were obtain-
ed from the periodic follow-up as usually conducted.
For statistical analysis the following tests were applied: Cramer's V
test, Kruskal Wallis test, univariate ANOVA, true Fisher test.
The clinical practice followed with uniformity by all the Depart-
ments required that the candidates for surgical implantation were se-
lected on the basis of informed consent, prolonged failure of the
conservative treatments with severe impact on QoL, no abnormality of
upper urinary tract and kidney function. The pre-operative assessment
included a 5 day voiding diary, the post-void residual evaluation,
serum creatinine determination, urine culture, kidney ultrasound and
videourodynamics. In the voiding diaries were recorded also the leak-
age episodes, degree of urgency and the pad used. The SNM implant
procedure was performed as previously described [24].The test period lasted for at least 3 weeks and the stimulation pa-
rameters (pulse width, frequency and amplitude) were individually
chosen for each patient on the basis of the best responses, with stimula-
tion below threshold. Eligibility criteria for the deﬁnitive implant were
represented by a positive neuroanatomical response to the stimulation
with clinical improvement in the symptoms and no side effects.3. Results
17 subjects agreed to complete the survey during a follow-up visit,
13 females and 4 males, mean age 49.8 ± 10.9 years. The disease dura-
tion before implant ranged from 4 to 40 years (mean 13.5± 9.2 years);
10 subjects (59%) had the relapsing remitting, 2 (12%) the secondary
progressive and 5 (29%) the primary progressive forms of the disease,
with a mean Expanded Disability Status Scale (EDSS) score of 5.8 ±
1.8 [25]. Thirteen subjects (77%) were paraparetic. Regarding LUTS, 4
patients (24%) had voiding symptoms, 7 (41%) storage symptoms and
6 (35%) mixed symptoms; 6 patients reported simultaneous constipa-
tion. No statistical differenceswere identiﬁed among these three groups
in baseline characteristics except for the anal tone, which resulted hy-
pertonic in 83% of patients with mixed symptoms (p = 0.032). The
mean baseline EDSS score was worse in mixed and voiding LUTS than
in the storage ones. The mean time from the implant was 52 ±
26 months (range 12–97 months). The electrical parameters have
been individually programmed and the number of reprogramming dur-
ing the period of observation ranged from an average of 0.9, in patients
with storage symptoms, to 3.0, in thosewithmixed LUTS. In ﬁve out of 6
cases with mixed symptoms the stimulation has been discontinued
after a mean time of 66 months (range 10–84 months) for disease pro-
gression in 2 cases and for loss of efﬁcacy in 3. The mean EDSS score
didn't change signiﬁcantly from baseline to the last follow-up evalua-
tion, but patients complaining of mixed symptoms presented a quicker
progressive MS (Table 1).
Regarding the subjective improvements, 75% of the total population
(100% of patients with storage, 75% with voiding and 40% with mixed
symptoms) replied positively to the question “After SNMdid you detect
any signiﬁcant and lasting improvement in your bladder symptoms?”
The change inQoLwas evaluated by theVAS after thequestion “How
muchhas your QoL changed?”with a score ranging from 0 (not at all) to
5 (very much). The average score reported was 2.9 ± 1.5 for the whole
population, 1.8 ± 1.4, 3.3 ± 1.0 and 3.6 ± 1.4 for patients respectively
with mixed, storage and voiding symptoms (Fig. 1). Furthermore,
there was a statistically signiﬁcant reduction in subjective urgency
level evaluated by the VAS – ranging from 0 (no urgency at all) to 5 (se-
vere urgency) – in patients with storage and mixed symptoms; they
passed from an average score of 3.6 ± 1.1 before SNM to 2.0 ± 1.3 dur-
ing SNM (p = 0.014) (Fig. 2).
Analyzing the subgroups, there was a statistically signiﬁcant reduc-
tion in the number of micturitions/day (from 14.3 ± 9.6 to 8.1 ± 3.7;
p = 0.012) and number of pads/day (from 3.5 ± 1.8 to 1.9 ± 2.4;
p = 0.033) in patients with storage and mixed symptoms. In subjects
with voiding and mixed symptoms was found a statistically signiﬁcant
reduction in number of catheterizations/day (from 3.1 ± 2.0 to 0.9 ±
1.0; p = 0.017) and residual volumes (from 195.0 ± 9.0 to 71.5 ±
63.3 ml; p = 0.018) and a statistically signiﬁcant increase in
Fig. 1. Quality of life changes with SNM at the time of survey compilation. Score ranging
from 0 (not at all) to 5 (very much).
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p = 0.016). In Figs. 3, 4, 5, 6 and 7 are shown these changes.Fig. 3.Micturition number/day at baseline (b) and last follow-up visit (fu).*Strong outlier
values; °outlier value.4. Discussion
Schmidt et al. introduced SNM for the treatment of different kinds of
LUTS refractory to conservative treatments [26]. In 2000 a multicenter,
international and prospective study of 581 patients found that SNM re-
duced by more than 50% the voiding frequency, incontinence episodes
and retention symptoms in patients with such intractable conditions,
but the study excluded patients with underlying neurologic disorders
[27].
SNMhas been also used in some cases of neurogenic bladder [14,16,
28] and also in neurogenic bladder caused byMS, though the few refer-
ences usually regard a small number of patients andmainlywith a short
or median follow-up [21–23,29]. Furthermore the use of SNM is
discouraged in MS for the progressive features of the disease [4] and a
limitation to the use of this therapy inMS patients is its contraindication
to magnetic resonance (MRI) examination.
InmanyMS patients the demyelination of the dorsal columns,which
determines the interruption of normal inhibitory signals coming from
sacral parasympathetic outﬂow tracts, can result in neurogenic detrusor
overactivity, which represents the most common problem experienced
during the course of the disease. Also voiding symptoms can be experi-
enced by MS patients when the urethral sphincter fails to relax in a
picture of detrusor-sphincter dyssynergia [3] or in case of detrusor
hypocontractility, reported in 20% of cases [30].
Another problem is the fact that MS nervous system lesions tend to
resolve and then recur in different patterns, resulting in unpredictable
changes in symptoms over time, and in any case this disease is generally
progressive, and hence the therapeutic response can vary. Therefore pa-
tients have to be clearly informed that the results of SNMmay be altered
by the evolution of their underlying disease.
Notwithstanding these considerations, many authors do not consid-
er MS a contra-indication for SNM. The few studies published on this
topic regard mainly urinary incontinence; only Marinkovic and Gillen
investigated pure urinary retention, reporting remarkably good results
[22].
Bosch and Groen observed in 4 MS women with refractory urge-
incontinence a reduction in incontinence episodes – from a mean of 4
to 0.3 per day –with SNM. Two womenwere completely dry and 1 im-
proved signiﬁcantly during the two year follow-up; in the last case the
urinary symptoms worsened with clinical progression of the disease
[21]. Subsequently their 4 cases were included in a series of 9 patients
[14]with neurogenic urge-incontinence resistant to conservative thera-
pies, due to MS in overall 5 cases. At 6 months, SNM resulted in all ofFig. 2. Subjective urgency level at baseline (retrospective) and at the time of survey com-
pilation. Score ranging from 0 (no urgency at all) to 5 (severe urgency).them having a marked symptomatic improvement in incontinence
with positive changes in everyday life: frequency improved from 16.1
to 8.2 voids per day and the mean volume per void correspondingly in-
creased from 115 to 249 ml with six patients completely dry. These re-
sults remained stable for an average of 43.6 months except that in two
MS patients. Moreover another MS patient had a short follow-up
(11 months). In conclusion 2 out of 5 subjects with MS have had a
long-lasting beneﬁt from SNM with a follow-up of 60 and 72 months.
Wallace et al. implanted 28 patients with neurogenic bladder
complaining of incontinence and/or urinary retention and among
them there were 13 MS. At a mean follow-up of 12.4 months they ob-
served a statistically signiﬁcant improvement in all the usual items re-
garding detrusor overactivity and also a reduction of 58% in the
number of self-catheterizations. Unfortunately MS patients are not dis-
tinguishable from other patients [16].
Recently Marinkovic and Gillen reported complete success in 86% of
14 MS females complaining of urinary retention: the pre-operativeFig. 4. Number of pads/day at baseline (b) and last follow-up visit (fu). °Outlier value.
Fig. 5. Voided volume (ml) at baseline (b) and last follow-up (fu). °Outlier value. Fig. 7. Residual volume (ml) at baseline (b) and last follow-up visit (fu).
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to void without intermittent catheterization at a follow-up of 4.3 years.
The authors outlined that the only 2 patient non-responders to SNM
were wheelchair-bound [22].
Minardi and Muzzonigro treated 15 patients and found that urinary
retention due to detrusor underactivity is not a good indication for SNM
while it should be offered in the case of refractory urge-incontinence or
urinary retention due to detrusor sphincter dyssynergia [23].
Most of these studies are included in a meta-analysis about
neurogenic bladder dysfunction treated with SNM which conﬁrms the
low number of MS patients investigated and their heterogeneity, with
50 MS cases out of 357 patients [29].
In none of the above studies reported have there been signiﬁcant
complications.
Also if the literature concerning SNM in MS is small, SNM seems to
have an inhibitory effect on neurological detrusor overactivity also if
the proportion of patients whose LUTS improved is much less than in
non-neurological pathologies.Fig. 6. Catheterization number/day at baseline (b) and last follow-up visit (fu).Our observational retrospective survey, regarding patients treated
with SNM for every type of LUTS, is the largest MS series studied to
date. SNM has been performed in a minority of Urology Units – some
of those more trained in neuro-urology – and overall has been rarely
used considering that only 17 patients had been implanted in a wide
geographic area.
In our experience, SNM has been a quite effective therapy for LUTS
with improvement in QoL in MS with lower EDSS. In fact, SNM has
worked better in patients with less severemotor impairment as report-
ed in previous studies [22,29]. In the present report the lack of a validat-
ed questionnaire on QoL could be a limitation but a VAS evaluation was
easier to perform, equally reliable and supported by objective urinary
data (reduction of leakage episodes and residual volume).
Moreover these results have been maintained over time in most of
patients and they have been detected in all the items at a medium
follow-up. The best responses have been observed in storage LUTS,
followed by the voiding ones. Poor and short-lasting beneﬁts have
been reported in the mixed LUTS, in connection with a quicker and
more aggressive form of the disease (EDSS scoreworsened in the course
of time compared to the other cases), and this could explain the de-
crease of SNM efﬁcacy over time observed in the majority of these pa-
tients (ﬁve out of six patients).
There is a signiﬁcant feature in our series of patients: it is not a se-
lected cohort but represents the real MS population. Regarding the gen-
der, our casuistry – with 4 men out of 17 patients – reﬂects the gender
prevalence ratio of MS, while in others reports are mainly analyzed
with only female patients. Furthermore we have analyzed every type
of LUTS whereas others authors focused only on incontinence or reten-
tion [12,21–23,29].5. Conclusion
In our experience SNM has obtained objective and subjective im-
provement of LUTS in most of the cases of MS with long-lasting beneﬁt.
Therefore it could be a therapeutic option in very selected cases of stor-
age and voiding symptoms, refractory to conservative treatments,
caused by a stable or slowly progressive MS without severe motor
impairment.
Storage LUTS have the best chance of amelioration, followed by the
voiding ones. SNM should be avoided in mixed symptoms and in cases
261E. Andretta et al. / Journal of the Neurological Sciences 347 (2014) 257–261of advanced disability, in order to maximize the cost–beneﬁt of this
therapy.
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